Clinical trials

Completed

An Open-label Study Evaluating Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops at Different Doses in Patients with Dry Eye

NGF0213

What is the purpose of this study?

The primary objective of this study was to assess the efficacy and safety of different doses of rhNGF when administered as eye drops to patients with Dry Eye.

Trial overview

Condition

Dry Eye Syndrome

Study Identifiers

NCT02101281

Study type

Safety and Tolerability after ascending or descending dose

Intervention

Biological: Recombinant Human nerve growth factor 20 µg/mL
Biological: Recombinant Recombinant Human nerve growth factor 4 µg/mL or 60 µg/mL

Phase

II

Start date:

Mar 2014 - Group1

Oct 2014 - Group2

End Date

Jan2015

Enrollment Goal

Group 1: 20 patients (rh-NGF 20 µg/mL)
Group 2: 20 patients (rh-NGF 4 or 60 µg/mL)

Going deep into the trial

Eligibility/Recruitment

Age

≥18 years old

Gender

Accepts healthy volunteers

Key Criteria

close

Inclusion

close

Exclusion

Some information about patients involvement

Study participation will last approximately 114 weeks and will include up to 11 visits to the study center

Desired Outcomes

close

Primary Outcomes

close

Secondary Outcomes

Find your nearest centre:

Loading...

loading...